"10.1371_journal.pmed.1000362","plos medicine","2010-11-02T00:00:00Z","Xavier Duval; Sylvie van der Werf; Thierry Blanchon; Anne Mosnier; Maude Bouscambert-Duchamp; Annick Tibi; Vincent Enouf; Cécile Charlois-Ou; Corine Vincent; Laurent Andreoletti; Florence Tubach; Bruno Lina; France Mentré; Catherine Leport; and the Bivir Study Group","Inserm CIC 007, APHP, Hôpital Bichat, Paris, France; Inserm U738, Paris, France; Université Paris Diderot, Paris 7, UFR de Médecine, site Bichat, Paris, France; Institut Pasteur, Centre National de Référence des virus influenzae (Région-Nord), Unité de Génétique Moléculaire des Virus à ARN, Paris, France; CNRS URA3015, Paris, France; Université Paris Diderot, Paris 7, UFR Sciences du Vivant, Paris, France; Inserm UPMC UMR-S 707, Faculté de médecine Pierre et Marie Curie, Paris, France; Université Pierre et Marie Curie, Paris 6, UFR de Médecine, U707, Paris, France; Réseau des Groupes Régionaux dObservation de la Grippe (GROG), Coordination nationale, Paris, France; Hospices Civils de Lyon, Centre National de Référence des virus influenzae (Région-Sud), GHE, Bron, France; Université Lyon 1, VirPatH, CNRS FRE 3011, Lyon, France; APHP- Agence Générale des Equipements et Produits de Santé, Unité Essais Cliniques, Paris, France; Université Paris Descartes, Paris 5, Faculté de Pharmacie, Paris, France; Université Paris Diderot, Paris 7, UFR de Médecine, site Bichat, Laboratoire de Recherche en Pathologie Infectieuse, Paris, France; APHP, Hôpital Bichat, Unité de Biostatistiques, Paris, France; Hôpital Robert Debré, Unité de Virologie médicale, Reims, France; Unité de Virologie Médicale et Moléculaire Faculté de Médecine Université Champagne-Ardenne IFR53/EA-4303, Reims, France; APHP Hôpital Bichat, Département dEpidémiologie, Biostatistiques et Recherche Clinique, Paris, France; APHP, Unité de Coordination des Risques Epidémiques et Biologiques, Paris, France","ICMJE criteria for authorship read and met: SvdW TB AM AT VE CCO CV LA FT BL FM CL. Agree with the manuscripts results and conclusions: XD SvdW TB AM MBD AT VE CCO CV LA FT BL FM CL. Designed the experiments/the study: XD SvdW TB AM VE CCO LA BL FM CL. Analyzed the data: XD SvdW TB AM CV LA FT BL FM CL. Collected data/did experiments for the study: XD SvdW TB AM MBD VE CCO FT BL FM CL. Enrolled patients: CCO. Wrote the first draft of the paper: XD SvdW TB BL FM CL. Contributed to the writing of the paper: XD SvdW TB AM MBD AT VE CCO LA FT BL FM CL. Enrolled investigators and took part in the epidemiological surveillance which gave the go-ahead to the study: AM. Responsible for data monitoring: FT. Obtained funding: FM CL.","XD has had a conference invitation from GSK and lecture fees from Roche and Gilead. AM has membership in the ministry of health advisory board on influenza; involvement in some epidemiological studies partially or fully granted by Roche and GSK, and travel grants from Roche for participation in scientific meetings. SVDW has had a conference invitation from GSK; research grant from GSK on unrelated subject; joined patent from institution with GSK on unrelated subject; travel grants for meetings from GSK; contribution to clinical trial financed by Roche; member of the advisory committee on influenza of the French ministry of health; is a member of ESWI; is a member of the scientific committee of the GEIG; and is vice-president of the GROG network. FM received fees from Roche, preclinical pharmacokinetic department, for a course on MONOLIX in December 2008. BL has had paid consultancy and board membership (Roche, GSK, Novartis, BioCryst, MedImmune), has had research grants from Roche and Sanofi-Pasteur, and had received travel grants and honoraria for speaking or participation at meetings (Roche, Sanofi-Pasteur).","2010","11","Xavier Duval","XD",15,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
